In contrast, CD4+ and CD8+ T-cell levels in the blood of MS patients are comparable to those observed in healthy individuals (Waschbisch et al., 2014), suggesting that the initiation of immune involvement in MS patients is a result of CD8+ T-cell expansion at the site of the lesion (Crawford et al., 2004). Here, CD8A is linked to myeloid sarcoma.